A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies Meeting Abstract
| Authors: | de Weger, V.; Lolkema, M. P.; Dickson, M.; Le Cesne, A.; Wagner, A.; Merqui-Roelvink, M.; Varga, A.; Tap, W.; Schwartz, G.; Demetri, G.; Zheng, W.; Tuffal, G.; Mace, S.; Miao, H.; Schellens, J. H. M.; De Jonge, M. |
| Abstract Title: | A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignancies |
| Meeting Title: | 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 50 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2014 Nov 18-21 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-11-01 |
| Start Page: | 121 |
| End Page: | 122 |
| Language: | English |
| ACCESSION: | WOS:000347755700379 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(14)70504-0 |
| Notes: | Meeting Abstract: 378 -- 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 18-21, 2014 -- Barcelona, SPAIN -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
